Restoring erythromycin efficacy by the repurposed drugs desloratadine and zinc gluconate as adjuvants via bacterial efflux pump inhibition
This study demonstrates that the repurposed drugs desloratadine and zinc gluconate act as effective efflux pump inhibitors that synergize with erythromycin to restore its efficacy against multidrug-resistant bacteria both in vitro and in a mouse model, a mechanism further validated by molecular docking and simulation studies targeting the AbeJ protein.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The Big Problem: The "Super-Door" in the Bacteria
Imagine bacteria as tiny fortresses. Inside these fortresses, they have special "super-doors" called efflux pumps. Normally, these doors let the bacteria breathe and eat. But when bacteria get tough (resistant), they start using these doors to kick out any medicine (antibiotics) that tries to enter.
Think of it like a bouncer at a club who is so good at his job that he throws every guest (the antibiotic) out the moment they try to walk in. Because of this, old antibiotics like erythromycin have become useless against these bacteria. The bacteria just pump the medicine right back out before it can do its job.
The New Idea: Using "Old Keys" to Jam the Door
The researchers asked a simple question: What if we don't build a new key (a new antibiotic), but instead find a way to jam the bouncer's hand so he can't open the door?
They looked at two common, everyday drugs that people already take for other reasons:
- Desloratadine: A common allergy medicine (like Claritin).
- Zinc Gluconate: A common zinc supplement (often taken for colds).
These aren't antibiotics. They are "adjuvants," which is a fancy word for "helpers." The goal was to see if these helpers could stop the bacterial bouncer (the efflux pump) and let the old antibiotic (erythromycin) finally get inside the fortress to kill the bacteria.
The Lab Tests: The "Zone of Inhibition" Game
First, the scientists tested this in a petri dish (a flat glass plate with bacteria growing on it).
- The Setup: They put a disk soaked in the antibiotic on the plate. Around it, they put disks with the allergy medicine or the zinc.
- The Result: When they used the antibiotic alone, the bacteria grew right up to the edge. But when they added the allergy medicine or zinc, the "safe zone" (where bacteria couldn't grow) got much bigger.
- The Takeaway: It's like the bouncer suddenly got distracted. The antibiotic could finally get in, and the bacteria started dying. The study found this worked well against four different types of tough bacteria, including E. coli and Staphylococcus aureus.
The Mouse Test: Healing the Lungs
Next, they moved to a living test. They used mice with weak immune systems (like people with very low white blood cell counts) and infected their lungs with a tough bacteria called Acinetobacter baumannii.
They divided the mice into groups:
- Sick Group: Got no treatment.
- Antibiotic Group: Got only erythromycin.
- Helper Groups: Got erythromycin plus either the allergy medicine or the zinc.
What happened?
- The mice that got only the antibiotic stayed very sick. They lost weight, had trouble breathing, and their lungs were heavy and inflamed (swollen with fluid and damage).
- The mice that got the antibiotic plus the helpers recovered much better.
- Weight: They gained weight back faster.
- Blood: Their white blood cell counts (the army fighting the infection) returned to normal levels.
- Lungs: When the scientists looked at the lungs under a microscope, the lungs of the "helper" groups looked almost healthy. The air sacs (alveoli) were intact, and there was much less inflammation. The lungs of the "antibiotic only" group still looked damaged.
The Computer Simulation: The "Virtual Lock and Key"
To understand why this worked, the scientists used powerful computers to simulate the interaction at a molecular level. They built a 3D model of the bacterial "bouncer" (a protein called AbeJ) and watched how the drugs interacted with it.
- The Docking: They saw that the allergy medicine (desloratadine) and the zinc fit perfectly into the "pocket" of the bouncer.
- The Jam: Once they were in, they held on tight (strong binding energy). It was like putting a wedge in a door hinge. The bouncer couldn't move anymore.
- The Stability: The computer showed that when these helpers were attached, the bouncer's structure became very stable and stopped working. The antibiotic (erythromycin) could then stay inside the bacteria and do its job.
The Conclusion
The paper concludes that Desloratadine and Zinc Gluconate are promising "helpers." They act like a jammer for the bacterial super-doors. By stopping the bacteria from pumping out the medicine, they allow an old, "obsolete" antibiotic (erythromycin) to work again.
Important Note: The paper strictly states these results are based on lab tests (petri dishes), mouse models, and computer simulations. The authors emphasize that while the results are very encouraging, these drugs are not yet approved for this specific use in humans, and more research is needed before they can be used in clinical practice.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.